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A B S T R A C T
Previous studies have found a strong association between HLA-B*1502 and carbamazepine-induced
Stevens–Johnson syndrome in Asian areas including Taiwan, Hongkong and Thailand. This study
explores the association between HLA-B*1502 allele and carbamazepine-induced cutaneous adverse
reactions in Han Chinese of southern China mainland, and ﬁnd the genetic marker that can predict
carbamazepine-induced cutaneous adverse reactions.
HLA-B*1502 allele genotyping was performed by a polymerase chain reaction–sequence speciﬁc
primers (PCR–SSP) method in 48 Han Chinese subjects who had carbamazepine-induced cutaneous
adverse reactions, including 9 severe cutaneous adverse reaction patients with Stevens–Johnson
syndrome (SJS) or toxic epidermal necrolysis (TEN) and 39 cutaneous adverse reaction patients with
maculopapular eruption (MPE). Meanwhile 80 carbamazepine-tolerant controls and 62 healthy
individuals were also tested.
The frequency of HLA-B*1502 allele among SJS/TEN patients (100%) is signiﬁcantly higher than
carbamazepine-tolerant controls (13.75%, P < 0.001) and healthy individuals (17.74%, P < 0.001). But the
frequency between MPE patients and carbamazepine-tolerant controls (25.64% vs.13.75%, P = 0.110) did
not have any signiﬁcant difference.
The data showed that HLA-B*1502 allele is strongly associated with carbamazepine-induced SJS/TEN
but not MPE in Han Chinese of southern China mainland.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Carbamazepine (CBZ) is widely used to treat epilepsy, bipolar
disorder, trigeminal neuralgia and chronic pain. However,
carbamazepine can cause many forms of adverse reactions,
from mild skin rash to serious blistering conditions such as
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN). The latter two disorders carry high mortality up to 30%.1
Recently, the associations between HLA-B*1502 and carbamaz-
epine-induced Stevens–Johnson syndrome or toxic epidermal
necrolysis (CBZ-SJS/TEN) had been detected by more and more
studies. In addition, the US FDA recommended to do genetic
screening of HLA-B*1502 in patients from Asian ancestry before
initiation of carbamazepine therapy.2 Nevertheless, up to now
there are few reports in southern China mainland possessing the
largest population of Asian. Hence, we report preliminary results
about the study in southern China mainland.* Corresponding author. Tel.: +86 13632378811; fax: +86 20 37864877.
E-mail addresses: zhoujq0215@163.com, 21324667@qq.com (J.-q. Zhou).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.02.0032. Subjects and methods
2.1. Subjects
All subjects in the study were recruited from outpatients and
inpatients in the First Afﬁliated Hospital of Sun Yat-sen University
between 1995 and 2010. A total of 48 cases fromunrelated families
were patients who developed cutaneous adverse reaction within
12 weeks after taking carbamazepine and for which no other
causes were found. They were classiﬁed into two groups according
to Roujeau’s diagnostic criteria.3 One group was diagnosed
Stevens–Johnson syndrome or toxic epidermal necrolysis, includ-
ing 9 patients (3 men and 6 women). Eight cases were diagnosed
SJS and one case was diagnosed TEN; the mean recipient age were
32.00  16.81. The other group was maculopapular eruption (MPE)
deﬁned as erythematous exanthem without blistering, pustulation,
mucosal or systemic involvement, including 39 patients (25 men and
14 women); the mean recipient age were 32.23  19.85. Meanwhile,
80 patients (46 men and 34 women) of carbamazepine-tolerance
were invested, who taked carbamazepine at least 3 months without
adverse effects; the mean age were 29. 57  16.22. Healthy
individuals comprised subjects without taked carbamazepine andvier Ltd. All rights reserved.
Table 1
Frequency of HLA-B*1502 genotype in three groups [n (%)].
Group n HLA-B*1502 positive HLA-B*1502 negative
CBZ-SJS/TEN 9 9(100)a,b,c 0(0)
CBZ-MPE 39 10(25.64) 29(74.36)
CBZ-tolerant 80 11(13.75) 69(86.25)
Healthy individuals 62 11(17.74) 51(82.26)
a Compared with CBZ-MPE group, x2 =16.907, P<0.001.
b Compared with CBZ-tolerant group x2 =34.543, P<0.001.
c Compared with normal individuals group x2 =26.281, P<0.001.
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healthy individuals group (27 men and 35 women), the mean age
were 38.08  13.60. The study was performed in accordance with the
Declaration of Helsinki and its amendments and the document of
informed consent was obtained from all subjects.
2.2. Genotyping
Genomic deoxyribonucleic acid (DNA) was isolated from
peripheral blood using the Genomic DNA Isolation Kit (Shanghai
Watsonbiot Technology Co., China). HLA-B*1502 genotype was
determined by polymerase chain reaction using sequence speciﬁc
primers (PCR-SSP).4 Four sets of HLA-speciﬁc primers (Pair1:
Forward primer [F1] 50-CGAGAGAGCCTGCGGAAC-30, reverse
primer [R1] 50-GCCCACTTCTGGAAGGTTCT-30; Pair2: [F2] 50-
CGCGAGTCCGAGGATGGC-30, [R2] 50-GCAGGTTCCGCAGGCTCT-30;
Pair3: [F3] 50-ACCGGAACACACAGATCTC-30, [R3] 50-GAGCCACTC-
CACGCACAGT-30; Pair4: [F4] 50-GGAGTATTGGGACCGGAAC-30, [R4]
50-GCCATACATCCTCTGGATGA -30)and 2 sets of internal control
primers (PairC1: [FC1] 50-TGCCAAGTGGAGCACCCAA-30, [RC1] 50-
GCATCTTGCTCTGTGCAGAT-30; PairC2: [FC2] 50-ATGATGTTGACCT
TTCCAGGG-30, [RC2] 50-TTCTGTAACTTTTCATCAGTTFC-30;) were
used to perform PCR.4,9 The ampliﬁed fragment length of Pair1 to
Pair4 PCR products were 1340 base pairs (bp), 125 bp, 562 bp,
369 bp respectively, while the PairC1 and PairC2 PCR products
were 796 bp and 256 bp. The PCR conditions consisted of a
denaturation step at 968 C for 60 s; 5 cycles of 968 C for 20 s, 708 C
for 45 s, and 728 C for 25 s; 21 cycles of 968 C for 25 s, 658 C for 50 s,
728 C for 30 s; 4 cycles of 968 C for 30 s, 558 C for 60 s, and 728 C for
90 s. Cool by ramping to 208 C for 30 s prior to termination of the
program. PCR products were analyzed by electrophoretic separa-
tion on 2% agarose gels, followed by direct visualization over an
ultraviolet transilluminator after ethidium bromide staining.
Presence of all 4 HLA-speciﬁc PCR products and 2 internal control
PCR products denotes HLA-B*1502.
2.3. Statistics
Data were counted by positive or negative for HLA-B*1502. Chi-
square test and Fisher’s exact test were used to analyze the
association between carbamazepine-induced cutaneous adverse
reactions and HLA-B*1502. The strength of association was
estimated by calculating the odds ratio.5 P-values  0.05 (two-
sided) were considered to indicate statistical signiﬁcance. Positive
predictive value, negative predictive value, sensitivity and
speciﬁcity were analyzed by ﬁxed formula.
3. Results
Frequency of HLA-B*1502 genotype in three groups was shown
in Table 1. All of the 9 carbamazepine-induced severe cutaneous
adverse reaction patients carried HLA-B*1502. It showed signiﬁ-
cant increase in HLA-B*1502 allele frequencywhen comparedwith
two control groups, carbamazepine-tolerant group (100% vs.
13.75%, x2 = 34.543, P < 0.001; OR = 114.826, 95% CI 6.25–
2,111.03) and healthy individuals group (100% vs.17.74%,
x2 = 26.281, P < 0.001; OR = 85.087, 95% CI 4.61–1569.48). But
there was no difference in the frequency of HLA-B*1502 allele
between the CBZ-MPE group and the control group (25.64% vs.
13.75%, x2 = 2.551, P = 0.110; OR = 2.163, 95% CI 0.828–5.649;
25.64% vs. 17.74%, x2 = 0.907, P = 0.341; OR = 1.599, 95% CI 0.606–
4.218). As the same, no signiﬁcant association was found between
carbamazepine-tolerant group and healthy individuals group
(13.75% vs. 17.74%, x2 = 0.425, P = 0.514).
When carbamazepine-tolerant group was used as control, the
presence of HLA-B*1502 had a 45% positive predictive value forCBZ-SJS/TEN, whereas its absence had a negative predictive value
of 100%. As the test for CBZ-SJS/TEN, HLA-B*1502 allele had 100%
sensitivity and 86.25% speciﬁcity.
4. Discussion
In healthy individuals, the frequency of HLA-B*1502 allele
observed in our study was 17.74%, which was a little higher than
the study in healthy Han Chinese by Li Yan (11.5%).6 We presumed
our small sample make the difference. However the allele
frequency of HLA-B*1502 was only 1–2% in prior studies of
European populations.7 The obviously low frequency of HLA-
B*1502 in European might explain the reason of rare morbility of
SJS/TEN in Caucasian compared with Chinese.
Our study explores the association between HLA-B*1502 and
carbamazepine-induced cutaneous adverse reaction in Han
Chinese living in southern China mainland possessing the most
Han Chinese in the world. Although our study obtained a limited
number of patients, all of 9 cases with CBZ-SJS/TEN carried HLA-
B*1502 allele. The difference of association with HLA-B*1502
allele was markedly signiﬁcant comparing with the controls.
Similar association was reported in other areas. Chung et al.
found that HLA-B*1502 allele was present in 100% of 44 CBZ–SJS
Han Chinese patients living in Taiwan but in only 3% of CBZ-
tolerant patients and in 9% of the control population.8 Since HLA-
B*1502 was showed strong association with CBZ–SJS/TEN in
Taiwan, similar result was also detected in Hongkong.9 A follow-
up study in Thai people, another Asian population who are non-
Han Chinese, got result in coincide with previous study in
Taiwan.10 But the association between HLA-B*1502 and CBZ-SJS/
TEN could not be conﬁrmed in Japanese,11 HLA-B*1502 was even
not detected in any of 486 healthy Japanese.12 Studies in
Caucasians found no association between HLA-B*1502 and CBZ-
SJS patients who were European ancestry.13 Thus, HLA-B*1502
allele did not exist in CBZ-SJS/TEN patients of all ethnicities. We
postulated the failure might be explained by differences in
linkage disequilibrium patterns between ethnic groups. It
prompted that genetic association of HLA-B*1502 and CBZ-
SJS/TEN is ethnicity speciﬁc.
Unlike CBZ-SJS/TEN, we genotyped HLA-B*1502 allele in CBZ-
MPE in Han Chinese of southern China mainland, no signiﬁcant
association was found when compared with frequency in the CBZ-
tolerant group or healthy individuals. The ﬁndingwas in accordance
with reports in Taiwan and Hongkong.9,14 SJS/TEN and MPE might
belong to different types of cutaneous adverse reactions, SJS/TEN
are characterized by bullous lesion, while MPE is non-bullous
reaction. So we considered that genetic association of carbamaze-
pine induced cutaneous adverse reactions is phenotype-speciﬁc.
In conclusion, we conﬁrmed the strong association between
HLA-B*1502 and CBZ-SJS/TEN in Han Chinese of southern China
mainland. On the contrary, no association between HLA-B*1502
and CBZ-MPE was observed. As a test for CBZ-SJS/TEN, it revealed
100% sensitivity, 86.25% speciﬁcity, 45% positive predictive value
and 100% negative predictive value of HLA-B*1502. Owing to data
in our study, we suggested HLA-B*1502 allele as a useful prediction
Q. Wang et al. / Seizure 20 (2011) 446–448448marker for carbamazepine-induced Stevens–Johnson syndrome
and toxic epidermal necrolysis in Han Chinese living in southern
China mainland.
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